Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors

Obstetrics and Gynecology

Volumn 117, Issue 6, 2011, Pages 1289-1297

  Ueland, Frederick R ^a,b,c,d   Desimone, Christopher P ^a,b,c   Seamon, Leigh G ^a,b,c   Miller, Rachel A ^a,b,c   Goodrich, Scott ^a,b,c   Podzielinski, Iwona ^a,b,c   Sokoll, Lori ^a,b,c   Smith, Alan ^a,b,c   Van Nagell, John R ^a,b,c   Zhang, Zhen ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Applied Clinical Intelligence   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; PREALBUMIN; TRANSFERRIN;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIVARIATE INDEX ASSAY; OVARY TUMOR; PATHOLOGY; PATIENT REFERRAL; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADULT; AGED; ALGORITHMS; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; REFERRAL AND CONSULTATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 79958152284     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821b5118     Document Type: Article

References (30)

1. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995;273:491-7.
2. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology 1997;11:95-105. (Pubitemid 28011746)
3. Le T, Giede C. Initial evaluation and referral guidelines for management of pelvic/ovarian masses. Joint SOGC/GOG/ SCC Clinical Practice Guideline. Journal Obstet Gynaecol Can 2009;31:668-73.
4. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. ACOG Committee Opinion No. Obstet Gynecol 2002;100:1413-6.
5. Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Rockville (MD): U.S. Department of Health and Human Services, 2006.
6. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589-98. (Pubitemid 43157622)
7. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000;18: 2327-40.
8. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol;99:447-61.
9. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80. (Pubitemid 43205479)
10. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42. (Pubitemid 34056463)
11. Ueland FR, Depriest PD, Desimone CP, Pavlik EJ, Lele SM, Kryscio RJ, et al. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol 2005;99:400-3. (Pubitemid 41502851)
12. Buys S, Partidge E, Greene M, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9. (Pubitemid 41540458)
13. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11. (Pubitemid 23339256)
14. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 2003;91:46-50. (Pubitemid 37188592)
15. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
16. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
17. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas J. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990;97: 922-9. (Pubitemid 20340625)
18. Tingulstad S, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52. (Pubitemid 29107011)
19. Zhang Z, Bast R, Yu Y, Li J, Sokoll L, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64: 5882-90.
20. Zhang Z, Chan D. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010;19:2995-9.
21. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41. (Pubitemid 40189908)
22. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841-8. (Pubitemid 47508749)
23. Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol 2006;49:448-58. (Pubitemid 44181418)
24. Maggina T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23.
25. Schutter E, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74:1398-406. (Pubitemid 24301797)
26. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
28. Bristow R, Zahurak M, del Carmen M, Gordon TA, Fox HE, Trimble EL, et al. Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 2004;93: 353-60. (Pubitemid 38507601)
29. Munoz KA, Harlan LC, Trible EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997; 15:3408-15.
30. Lee CK, Pires de Miranda M, Ledermann J, Ruiz de Elvira MC, Nelstrop AE, Lambert HE, et al. Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy. Eur J Cancer 1999; 35:727-32. (Pubitemid 29258141)